1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
- Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
- Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
- Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
- Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
- 2019
-
A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies
Perani, Daniela ; Iaccarino, Leonardo ; Lammertsma, Adriaan A. ; Windhorst, Albert D. ; Edison, Paul ; Boellaard, Ronald ; Hansson, Oskar LU
; Nordberg, Agneta
and Jacobs, Andreas H.
(2019)
In Alzheimer's and Dementia
15(8).
p.1081-1103
Mark
- Test–retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
- Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum
- Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
- 2018
- A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus